Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of eslicarbazepine acetate
once-daily at doses of 400 mg, 800 mg and 1200 mg compared with placebo as adjunctive therapy
in patients with refractory partial epilepsy over a 12-week maintenance period. Patients who
complete Part I may enter a 1-year open-label extension.